Literature DB >> 20829621

Neuropsychiatric disorders in Cushing's syndrome.

Alberto M Pereira1, Jitske Tiemensma, Johannes A Romijn.   

Abstract

Glucocorticoids are crucial in the initiation and consolidation of the stress response. Patients with active Cushing's syndrome (CS) are exposed to excessive endogenous glucocorticoid levels. In these patients, psychopathology is often being observed. The most common co-morbid disorder is major depression, but to a lesser extent mania and anxiety disorders have also been reported. A severe clinical presentation of CS often also includes depression. Reduction of glucocorticoid synthesis or action, either with metyrapone, ketoconazole, or mifepristone, rather than treatment with antidepressant drugs, is generally successful in relieving depressive symptoms, as well as other disabling symptoms. Following successful surgical treatment of hypercortisolism, both physical and psychiatric signs and symptoms improve substantially. However, it appears that patients do not completely return to their premorbid level of functioning and persistent impairment of quality of life and cognitive function has been reported despite long-term cure. At present, it is not clear whether, and to which extent, psychopathology still affects general well-being after long-term cure of CS.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20829621     DOI: 10.1159/000314317

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  44 in total

1.  A specific nursing educational program in patients with Cushing's syndrome.

Authors:  M Antonia Martínez-Momblán; Carmen Gómez; Alicia Santos; Nuria Porta; Julia Esteve; Inmaculada Úbeda; Irene Halperin; Beatriz Campillo; Montserrat Guillaumet; Susan M Webb; Eugenia Resmini
Journal:  Endocrine       Date:  2015-09-23       Impact factor: 3.633

2.  Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.

Authors:  S Cannavo; E Messina; A Albani; F Ferrau; V Barresi; S Priola; F Esposito; F Angileri
Journal:  Endocrine       Date:  2015-04-16       Impact factor: 3.633

3.  Systemic and Local Corticosteroid Use Is Associated with Reduced Executive Cognition, and Mood and Anxiety Disorders.

Authors:  Mesut Savas; Christiaan H Vinkers; Judith G M Rosmalen; Catharina A Hartman; Vincent L Wester; Erica L T van den Akker; Anand M Iyer; Bruce S McEwen; Elisabeth F C van Rossum
Journal:  Neuroendocrinology       Date:  2019-06-21       Impact factor: 4.914

4.  Clinical score system in the treatment of Cushing's disease: failure to identify discriminative variables from the German Cushing's Registry.

Authors:  Mareike R Stieg; Matthias K Auer; Christina Berr; Julia Fazel; Martin Reincke; Stephanie Zopp; Alexander Yassouridis; Günter K Stalla
Journal:  Pituitary       Date:  2019-04       Impact factor: 4.107

5.  White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study.

Authors:  Patricia Pires; Alicia Santos; Yolanda Vives-Gilabert; Susan M Webb; Aitor Sainz-Ruiz; Eugenia Resmini; Iris Crespo; Manel de Juan-Delago; Beatriz Gómez-Anson
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 6.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

7.  Poverty and Awakening Cortisol in Adolescence: The Importance of Timing in Early Life.

Authors:  Michael J McFarland; Mark D Hayward
Journal:  Soc Ment Health       Date:  2014-03

8.  Chronic non-invasive corticosterone administration abolishes the diurnal pattern of tph2 expression.

Authors:  Nina C Donner; Christian D Montoya; Jodi L Lukkes; Christopher A Lowry
Journal:  Psychoneuroendocrinology       Date:  2011-09-15       Impact factor: 4.905

9.  Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.

Authors:  R van der Pas; C de Bruin; A M Pereira; J A Romijn; R T Netea-Maier; A R Hermus; P M Zelissen; F H de Jong; A J van der Lely; W W de Herder; S M Webb; S W J Lamberts; L J Hofland; R A Feelders
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

10.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.